Generics Global Industry Guide 2017

Global Generics industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value and volume 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Questions Answered

– What was the size of the global generics market by value in 2016?

– What will be the size of the global generics market in 2021?

– What factors are affecting the strength of competition in the global generics market?

– How has the market performed over the last five years?

– Who are the top competitors in the global generics market?

Scope

Essential resource for top-line data and analysis covering the global generics market. Includes market size and segmentation data, textual and graphical analysis of market growth trends and leading companies.

– For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.

– The market value is evaluated at ex-factory prices.

– Market volume is quantified here as the percentage of the total ethical pharmaceutical market volume in a country or region which is accounted for by generic drugs. It is therefore a generics penetration rate measure, not an absolute measure of market volume.

– All currency conversions were calculated at constant average annual 2015 exchange rates.

Reasons to buy

#NAME?

Table of Contents

Table of Contents

EXECUTIVE SUMMARY

Market value

Market value forecast

Market volume

Market volume forecast

Geography segmentation

Introduction

What is this report about?

Who is the target reader?

How to use this report

Definitions

Global Generics

Market Overview

Market Data

Market Segmentation

Market outlook

Five forces analysis

Generics in Asia-Pacific

Market Overview

Market Data

Market Segmentation

Market outlook

Five forces analysis

Generics in Europe

Market Overview

Market Data

Market Segmentation

Market outlook

Five forces analysis

Generics in France

Market Overview

Market Data

Market Segmentation

Market outlook

Five forces analysis

Macroeconomic indicators

Generics in Germany

Market Overview

Market Data

Market Segmentation

Market outlook

Five forces analysis

Macroeconomic indicators

Generics in Italy

Market Overview

Market Data

Market Segmentation

Market outlook

Five forces analysis

Macroeconomic indicators

Generics in Japan

Market Overview

Market Data

Market Segmentation

Market outlook

Five forces analysis

Macroeconomic indicators

Generics in Australia

Market Overview

Market Data

Market Segmentation

Market outlook

Five forces analysis

Macroeconomic indicators

Generics in Canada

Market Overview

Market Data

Market Segmentation

Market outlook

Five forces analysis

Macroeconomic indicators

Generics in China

Market Overview

Market Data

Market Segmentation

Market outlook

Five forces analysis

Macroeconomic indicators

Generics in The Netherlands

Market Overview

Market Data

Market Segmentation

Market outlook

Five forces analysis

Macroeconomic indicators

Generics in Spain

Market Overview

Market Data

Market Segmentation

Market outlook

Five forces analysis

Macroeconomic indicators

Generics in The United Kingdom

Market Overview

Market Data

Market Segmentation

Market outlook

Five forces analysis

Macroeconomic indicators

Generics in The United States

Market Overview

Market Data

Market Segmentation

Market outlook

Five forces analysis

Macroeconomic indicators

Company Profiles

Leading companies

Appendix

Methodology

About MarketLine

List of Tables

List of Tables

Table 1: Global generics market value: $ billion, 201216

Table 2: Global generics market volume: % of total pharma volume, 201216

Table 3: Global generics market geography segmentation: $ billion, 2016

Table 4: Global generics market value forecast: $ billion, 201621

Table 5: Global generics market volume forecast: % of total pharma volume, 201621

Table 6: Asia-Pacific generics market value: $ billion, 201216

Table 7: AsiaPacific generics market volume: % of total pharma volume, 201216

Table 8: AsiaPacific generics market geography segmentation: $ billion, 2016

Table 9: Asia-Pacific generics market value forecast: $ billion, 201621

Table 10: AsiaPacific generics market volume forecast: % of total pharma volume, 201621

Table 11: Europe generics market value: $ billion, 201216

Table 12: Europe generics market volume: % of total pharma volume, 201216

Table 13: Europe generics market geography segmentation: $ billion, 2016

Table 14: Europe generics market value forecast: $ billion, 201621

Table 15: Europe generics market volume forecast: % of total pharma volume, 201621

Table 16: France generics market value: $ billion, 201216

Table 17: France generics market volume: % of total pharma volume, 201216

Table 18: France generics market geography segmentation: $ billion, 2016

Table 19: France generics market value forecast: $ billion, 201621

Table 20: France generics market volume forecast: % of total pharma volume, 201621

Table 21: France size of population (million), 201216

Table 22: France gdp (constant 2005 prices, $ billion), 201216

Table 23: France gdp (current prices, $ billion), 201216

Table 24: France inflation, 201216

Table 25: France consumer price index (absolute), 201216

Table 26: France exchange rate, 201216

Table 27: Germany generics market value: $ billion, 201216

Table 28: Germany generics market volume: % of total pharma volume, 201216

Table 29: Germany generics market geography segmentation: $ billion, 2016

Table 30: Germany generics market value forecast: $ billion, 201621

Table 31: Germany generics market volume forecast: % of total pharma volume, 201621

Table 32: Germany size of population (million), 201216

Table 33: Germany gdp (constant 2005 prices, $ billion), 201216

Table 34: Germany gdp (current prices, $ billion), 201216

Table 35: Germany inflation, 201216

Table 36: Germany consumer price index (absolute), 201216

Table 37: Germany exchange rate, 201216

Table 38: Italy generics market value: $ billion, 201216

Table 39: Italy generics market volume: % of total pharma volume, 201216

Table 40: Italy generics market geography segmentation: $ billion, 2016

Table 41: Italy generics market value forecast: $ billion, 201621

Table 42: Italy generics market volume forecast: % of total pharma volume, 201621

Table 43: Italy size of population (million), 201216

Table 44: Italy gdp (constant 2005 prices, $ billion), 201216

Table 45: Italy gdp (current prices, $ billion), 201216

Table 46: Italy inflation, 201216

Table 47: Italy consumer price index (absolute), 201216

Table 48: Italy exchange rate, 201216

Table 49: Japan generics market value: $ billion, 201216

Table 50: Japan generics market volume: % of total pharma volume, 201216

Table 51: Japan generics market geography segmentation: $ billion, 2016

Table 52: Japan generics market value forecast: $ billion, 201621

Table 53: Japan generics market volume forecast: % of total pharma volume, 201621

Table 54: Japan size of population (million), 201216

Table 55: Japan gdp (constant 2005 prices, $ billion), 201216

Table 56: Japan gdp (current prices, $ billion), 201216

Table 57: Japan inflation, 201216

Table 58: Japan consumer price index (absolute), 201216

Table 59: Japan exchange rate, 201216

Table 60: Australia generics market value: $ billion, 201216

Table 61: Australia generics market volume: % of total pharma volume, 201216

Table 62: Australia generics market geography segmentation: $ billion, 2016

Table 63: Australia generics market value forecast: $ billion, 201621

Table 64: Australia generics market volume forecast: % of total pharma volume, 201621

Table 65: Australia size of population (million), 201216

Table 66: Australia gdp (constant 2005 prices, $ billion), 201216

Table 67: Australia gdp (current prices, $ billion), 201216

Table 68: Australia inflation, 201216

Table 69: Australia consumer price index (absolute), 201216

Table 70: Australia exchange rate, 201216

Table 71: Canada generics market value: $ billion, 201216

Table 72: Canada generics market volume: % of total pharma volume, 201216

Table 73: Canada generics market geography segmentation: $ billion, 2016

Table 74: Canada generics market value forecast: $ billion, 201621

Table 75: Canada generics market volume forecast: % of total pharma volume, 201621

Table 76: Canada size of population (million), 201216

Table 77: Canada gdp (constant 2005 prices, $ billion), 201216

Table 78: Canada gdp (current prices, $ billion), 201216

Table 79: Canada inflation, 201216

Table 80: Canada consumer price index (absolute), 201216

Table 81: Canada exchange rate, 201216

Table 82: China generics market value: $ billion, 201216

Table 83: China generics market volume: % of total pharma volume, 201216

Table 84: China generics market geography segmentation: $ billion, 2016

Table 85: China generics market value forecast: $ billion, 201621

Table 86: China generics market volume forecast: % of total pharma volume, 201621

Table 87: China size of population (million), 201216

Table 88: China gdp (constant 2005 prices, $ billion), 201216

Table 89: China gdp (current prices, $ billion), 201216

Table 90: China inflation, 201216

Table 91: China consumer price index (absolute), 201216

Table 92: China exchange rate, 201216

Table 93: Netherlands generics market value: $ billion, 201216

Table 94: Netherlands generics market volume: % of total pharma volume, 201216

Table 95: Netherlands generics market geography segmentation: $ billion, 2016

Table 96: Netherlands generics market value forecast: $ billion, 201621

Table 97: Netherlands generics market volume forecast: % of total pharma volume, 201621

Table 98: Netherlands size of population (million), 201216

Table 99: Netherlands gdp (constant 2005 prices, $ billion), 201216

Table 100: Netherlands gdp (current prices, $ billion), 201216

Table 101: Netherlands inflation, 201216

Table 102: Netherlands consumer price index (absolute), 201216

Table 103: Netherlands exchange rate, 201216

Table 104: Spain generics market value: $ billion, 201216

Table 105: Spain generics market volume: % of total pharma volume, 201216

Table 106: Spain generics market geography segmentation: $ billion, 2016

Table 107: Spain generics market value forecast: $ billion, 201621

Table 108: Spain generics market volume forecast: % of total pharma volume, 201621

Table 109: Spain size of population (million), 201216

Table 110: Spain gdp (constant 2005 prices, $ billion), 201216

Table 111: Spain gdp (current prices, $ billion), 201216

Table 112: Spain inflation, 201216

Table 113: Spain consumer price index (absolute), 201216

Table 114: Spain exchange rate, 201216

Table 115: United Kingdom generics market value: $ billion, 201216

Table 116: United Kingdom generics market volume: % of total pharma volume, 201216

Table 117: United Kingdom generics market geography segmentation: $ billion, 2016

Table 118: United Kingdom generics market value forecast: $ billion, 201621

Table 119: United Kingdom generics market volume forecast: % of total pharma volume, 201621

Table 120: United Kingdom size of population (million), 201216

Table 121: United Kingdom gdp (constant 2005 prices, $ billion), 201216

Table 122: United Kingdom gdp (current prices, $ billion), 201216

Table 123: United Kingdom inflation, 201216

Table 124: United Kingdom consumer price index (absolute), 201216

Table 125: United Kingdom exchange rate, 201216

Table 126: United States generics market value: $ billion, 201216

Table 127: United States generics market volume: % of total pharma volume, 201216

Table 128: United States generics market geography segmentation: $ billion, 2016

Table 129: United States generics market value forecast: $ billion, 201621

Table 130: United States generics market volume forecast: % of total pharma volume, 201621

Table 131: United States size of population (million), 201216

Table 132: United States gdp (constant 2005 prices, $ billion), 201216

Table 133: United States gdp (current prices, $ billion), 201216

Table 134: United States inflation, 201216

Table 135: United States consumer price index (absolute), 201216

Table 136: United States exchange rate, 201215

Table 137: Allergan plc: key facts

Table 138: Allergan plc: key financials ($)

Table 139: Allergan plc: key financial ratios

Table 140: Mylan Inc.: key facts

Table 141: Mylan Inc.: key financials ($)

Table 142: Mylan Inc.: key financial ratios

Table 143: Sandoz International GmbH: key facts

Table 144: Teva Pharmaceutical Industries Limited: key facts

Table 145: Teva Pharmaceutical Industries Limited: key financials ($)

Table 146: Teva Pharmaceutical Industries Limited: key financial ratios

Table 147: Sun Pharmaceutical Industries Ltd.: key facts

Table 148: Sun Pharmaceutical Industries Ltd.: key financials ($)

Table 149: Sun Pharmaceutical Industries Ltd.: key financials (Rs.)

Table 150: Sun Pharmaceutical Industries Ltd.: key financial ratios

Table 151: Sanofi SA: key facts

Table 152: Sanofi SA: key financials ($)

Table 153: Sanofi SA: key financials (€)

Table 154: Sanofi SA: key financial ratios

Table 155: Les Laboratoires Servier: key facts

Table 156: STADA Arzneimittel AG: key facts

Table 157: STADA Arzneimittel AG: key financials ($)

Table 158: STADA Arzneimittel AG: key financials (€)

Table 159: STADA Arzneimittel AG: key financial ratios

Table 160: Daiichi Sankyo Co., Ltd.: key facts

Table 161: Daiichi Sankyo Co., Ltd.: key financials ($)

Table 162: Daiichi Sankyo Co., Ltd.: key financials (Â¥)

Table 163: Daiichi Sankyo Co., Ltd.: key financial ratios

Table 164: Sawai Pharmaceutical Co., Ltd.: key facts

Table 165: Sawai Pharmaceutical Co., Ltd.: key financials ($)

Table 166: Sawai Pharmaceutical Co., Ltd.: key financials (Â¥)

Table 167: Sawai Pharmaceutical Co., Ltd.: key financial ratios

Table 168: Aspen Pharmacare Holdings Ltd: key facts

Table 169: Aspen Pharmacare Holdings Ltd: key financials ($)

Table 170: Aspen Pharmacare Holdings Ltd: key financials (ZAR)

Table 171: Aspen Pharmacare Holdings Ltd: key financial ratios

Table 172: Apotex, Inc.: key facts

Table 173: China Grand Pharmaceutical and Healthcare Holdings Limited: key facts

Table 174: China Grand Pharmaceutical and Healthcare Holdings Limited: key financials ($)

Table 175: China Grand Pharmaceutical and Healthcare Holdings Limited: key financials (CNY)

Table 176: China Grand Pharmaceutical and Healthcare Holdings Limited: key financial ratios

Table 177: Esteve Group: key facts

List of Figures

List of Figures

Figure 1: Global generics market value: $ billion, 201216

Figure 2: Global generics market volume: % of total pharma volume, 201216

Figure 3: Global generics market geography segmentation: % share, by value, 2016

Figure 4: Global generics market value forecast: $ billion, 201621

Figure 5: Global generics market volume forecast: % of total pharma volume, 201621

Figure 6: Forces driving competition in the global generics market, 2016

Figure 7: Drivers of buyer power in the global generics market, 2016

Figure 8: Drivers of supplier power in the global generics market, 2016

Figure 9: Factors influencing the likelihood of new entrants in the global generics market, 2016

Figure 10: Factors influencing the threat of substitutes in the global generics market, 2016

Figure 11: Drivers of degree of rivalry in the global generics market, 2016

Figure 12: Asia-Pacific generics market value: $ billion, 201216

Figure 13: AsiaPacific generics market volume: % of total pharma volume, 201216

Figure 14: AsiaPacific generics market geography segmentation: % share, by value, 2016

Figure 15: Asia-Pacific generics market value forecast: $ billion, 201621

Figure 16: AsiaPacific generics market volume forecast: % of total pharma volume, 201621

Figure 17: Forces driving competition in the generics market in Asia-Pacific, 2016

Figure 18: Drivers of buyer power in the generics market in Asia-Pacific, 2016

Figure 19: Drivers of supplier power in the generics market in Asia-Pacific, 2016

Figure 20: Factors influencing the likelihood of new entrants in the generics market in Asia-Pacific, 2016

Figure 21: Factors influencing the threat of substitutes in the generics market in Asia-Pacific, 2016

Figure 22: Drivers of degree of rivalry in the generics market in Asia-Pacific, 2016

Figure 23: Europe generics market value: $ billion, 201216

Figure 24: Europe generics market volume: % of total pharma volume, 201216

Figure 25: Europe generics market geography segmentation: % share, by value, 2016

Figure 26: Europe generics market value forecast: $ billion, 201621

Figure 27: Europe generics market volume forecast: % of total pharma volume, 201621

Figure 28: Forces driving competition in the generics market in Europe, 2016

Figure 29: Drivers of buyer power in the generics market in Europe, 2016

Figure 30: Drivers of supplier power in the generics market in Europe, 2016

Figure 31: Factors influencing the likelihood of new entrants in the generics market in Europe, 2016

Figure 32: Factors influencing the threat of substitutes in the generics market in Europe, 2016

Figure 33: Drivers of degree of rivalry in the generics market in Europe, 2016

Figure 34: France generics market value: $ billion, 201216

Figure 35: France generics market volume: % of total pharma volume, 201216

Figure 36: France generics market geography segmentation: % share, by value, 2016

Figure 37: France generics market value forecast: $ billion, 201621

Figure 38: France generics market volume forecast: % of total pharma volume, 201621

Figure 39: Forces driving competition in the generics market in France, 2016

Figure 40: Drivers of buyer power in the generics market in France, 2016

Figure 41: Drivers of supplier power in the generics market in France, 2016

Figure 42: Factors influencing the likelihood of new entrants in the generics market in France, 2016

Figure 43: Factors influencing the threat of substitutes in the generics market in France, 2016

Figure 44: Drivers of degree of rivalry in the generics market in France, 2016

Figure 45: Germany generics market value: $ billion, 201216

Figure 46: Germany generics market volume: % of total pharma volume, 201216

Figure 47: Germany generics market geography segmentation: % share, by value, 2016

Figure 48: Germany generics market value forecast: $ billion, 201621

Figure 49: Germany generics market volume forecast: % of total pharma volume, 201621

Figure 50: Forces driving competition in the generics market in Germany, 2016

Figure 51: Drivers of buyer power in the generics market in Germany, 2016

Figure 52: Drivers of supplier power in the generics market in Germany, 2016

Figure 53: Factors influencing the likelihood of new entrants in the generics market in Germany, 2016

Figure 54: Factors influencing the threat of substitutes in the generics market in Germany, 2016

Figure 55: Drivers of degree of rivalry in the generics market in Germany, 2016

Figure 56: Italy generics market value: $ billion, 201216

Figure 57: Italy generics market volume: % of total pharma volume, 201216

Figure 58: Italy generics market geography segmentation: % share, by value, 2016

Figure 59: Italy generics market value forecast: $ billion, 201621

Figure 60: Italy generics market volume forecast: % of total pharma volume, 201621

Figure 61: Forces driving competition in the generics market in Italy, 2016

Figure 62: Drivers of buyer power in the generics market in Italy, 2016

Figure 63: Drivers of supplier power in the generics market in Italy, 2016

Figure 64: Factors influencing the likelihood of new entrants in the generics market in Italy, 2016

Figure 65: Factors influencing the threat of substitutes in the generics market in Italy, 2016

Figure 66: Drivers of degree of rivalry in the generics market in Italy, 2016

Figure 67: Japan generics market value: $ billion, 201216

Figure 68: Japan generics market volume: % of total pharma volume, 201216

Figure 69: Japan generics market geography segmentation: % share, by value, 2016

Figure 70: Japan generics market value forecast: $ billion, 201621

Figure 71: Japan generics market volume forecast: % of total pharma volume, 201621

Figure 72: Forces driving competition in the generics market in Japan, 2016

Figure 73: Drivers of buyer power in the generics market in Japan, 2016

Figure 74: Drivers of supplier power in the generics market in Japan, 2016

Figure 75: Factors influencing the likelihood of new entrants in the generics market in Japan, 2016

Figure 76: Factors influencing the threat of substitutes in the generics market in Japan, 2016

Figure 77: Drivers of degree of rivalry in the generics market in Japan, 2016

Figure 78: Australia generics market value: $ billion, 201216

Figure 79: Australia generics market volume: % of total pharma volume, 201216

Figure 80: Australia generics market geography segmentation: % share, by value, 2016

Figure 81: Australia generics market value forecast: $ billion, 201621

Figure 82: Australia generics market volume forecast: % of total pharma volume, 201621

Figure 83: Forces driving competition in the generics market in Australia, 2016

Figure 84: Drivers of buyer power in the generics market in Australia, 2016

Figure 85: Drivers of supplier power in the generics market in Australia, 2016

Figure 86: Factors influencing the likelihood of new entrants in the generics market in Australia, 2016

Figure 87: Factors influencing the threat of substitutes in the generics market in Australia, 2016

Figure 88: Drivers of degree of rivalry in the generics market in Australia, 2016

Figure 89: Canada generics market value: $ billion, 201216

Figure 90: Canada generics market volume: % of total pharma volume, 201216

Figure 91: Canada generics market geography segmentation: % share, by value, 2016

Figure 92: Canada generics market value forecast: $ billion, 201621

Figure 93: Canada generics market volume forecast: % of total pharma volume, 201621

Figure 94: Forces driving competition in the generics market in Canada, 2016

Figure 95: Drivers of buyer power in the generics market in Canada, 2016

Figure 96: Drivers of supplier power in the generics market in Canada, 2016

Figure 97: Factors influencing the likelihood of new entrants in the generics market in Canada, 2016

Figure 98: Factors influencing the threat of substitutes in the generics market in Canada, 2016

Figure 99: Drivers of degree of rivalry in the generics market in Canada, 2016

Figure 100: China generics market value: $ billion, 201216

Figure 101: China generics market volume: % of total pharma volume, 201216

Figure 102: China generics market geography segmentation: % share, by value, 2016

Figure 103: China generics market value forecast: $ billion, 201621

Figure 104: China generics market volume forecast: % of total pharma volume, 201621

Figure 105: Forces driving competition in the generics market in China, 2016

Figure 106: Drivers of buyer power in the generics market in China, 2016

Figure 107: Drivers of supplier power in the generics market in China, 2016

Figure 108: Factors influencing the likelihood of new entrants in the generics market in China, 2016

Figure 109: Factors influencing the threat of substitutes in the generics market in China, 2016

Figure 110: Drivers of degree of rivalry in the generics market in China, 2016

Figure 111: Netherlands generics market value: $ billion, 201216

Figure 112: Netherlands generics market volume: % of total pharma volume, 201216

Figure 113: Netherlands generics market geography segmentation: % share, by value, 2016

Figure 114: Netherlands generics market value forecast: $ billion, 201621

Figure 115: Netherlands generics market volume forecast: % of total pharma volume, 201621

Figure 116: Forces driving competition in the generics market in the Netherlands, 2016

Figure 117: Drivers of buyer power in the generics market in the Netherlands, 2016

Figure 118: Drivers of supplier power in the generics market in the Netherlands, 2016

Figure 119: Factors influencing the likelihood of new entrants in the generics market in the Netherlands, 2016

Figure 120: Factors influencing the threat of substitutes in the generics market in the Netherlands, 2016

Figure 121: Drivers of degree of rivalry in the generics market in the Netherlands, 2016

Figure 122: Spain generics market value: $ billion, 201216

Figure 123: Spain generics market volume: % of total pharma volume, 201216

Figure 124: Spain generics market geography segmentation: % share, by value, 2016

Figure 125: Spain generics market value forecast: $ billion, 201621

Figure 126: Spain generics market volume forecast: % of total pharma volume, 201621

Figure 127: Forces driving competition in the generics market in Spain, 2016

Figure 128: Drivers of buyer power in the generics market in Spain, 2016

Figure 129: Drivers of supplier power in the generics market in Spain, 2016

Figure 130: Factors influencing the likelihood of new entrants in the generics market in Spain, 2016

Figure 131: Factors influencing the threat of substitutes in the generics market in Spain, 2016

Figure 132: Drivers of degree of rivalry in the generics market in Spain, 2016

Figure 133: United Kingdom generics market value: $ billion, 201216

Figure 134: United Kingdom generics market volume: % of total pharma volume, 201216

Figure 135: United Kingdom generics market geography segmentation: % share, by value, 2016

Figure 136: United Kingdom generics market value forecast: $ billion, 201621

Figure 137: United Kingdom generics market volume forecast: % of total pharma volume, 201621

Figure 138: Forces driving competition in the generics market in the United Kingdom, 2016

Figure 139: Drivers of buyer power in the generics market in the United Kingdom, 2016

Figure 140: Drivers of supplier power in the generics market in the United Kingdom, 2016

Figure 141: Factors influencing the likelihood of new entrants in the generics market in the United Kingdom, 2016

Figure 142: Factors influencing the threat of substitutes in the generics market in the United Kingdom, 2016

Figure 143: Drivers of degree of rivalry in the generics market in the United Kingdom, 2016

Figure 144: United States generics market value: $ billion, 201216

Figure 145: United States generics market volume: % of total pharma volume, 201216

Figure 146: United States generics market geography segmentation: % share, by value, 2016

Figure 147: United States generics market value forecast: $ billion, 201621

Figure 148: United States generics market volume forecast: % of total pharma volume, 201621

Figure 149: Forces driving competition in the generics market in the United States, 2016

Figure 150: Drivers of buyer power in the generics market in the United States, 2016

Figure 151: Drivers of supplier power in the generics market in the United States, 2016

Figure 152: Factors influencing the likelihood of new entrants in the generics market in the United States, 2016

Figure 153: Factors influencing the threat of substitutes in the generics market in the United States, 2016

Figure 154: Drivers of degree of rivalry in the generics market in the United States, 2016

Figure 155: Allergan plc: revenues & profitability

Figure 156: Allergan plc: assets & liabilities

Figure 157: Mylan Inc.: revenues & profitability

Figure 158: Mylan Inc.: assets & liabilities

Figure 159: Teva Pharmaceutical Industries Limited: revenues & profitability

Figure 160: Teva Pharmaceutical Industries Limited: assets & liabilities

Figure 161: Sun Pharmaceutical Industries Ltd.: revenues & profitability

Figure 162: Sun Pharmaceutical Industries Ltd.: assets & liabilities

Figure 163: Sanofi SA: revenues & profitability

Figure 164: Sanofi SA: assets & liabilities

Figure 165: STADA Arzneimittel AG: revenues & profitability

Figure 166: STADA Arzneimittel AG: assets & liabilities

Figure 167: Daiichi Sankyo Co., Ltd.: revenues & profitability

Figure 168: Daiichi Sankyo Co., Ltd.: assets & liabilities

Figure 169: Sawai Pharmaceutical Co., Ltd.: revenues & profitability

Figure 170: Sawai Pharmaceutical Co., Ltd.: assets & liabilities

Figure 171: Aspen Pharmacare Holdings Ltd: revenues & profitability

Figure 172: Aspen Pharmacare Holdings Ltd: assets & liabilities

Figure 173: China Grand Pharmaceutical and Healthcare Holdings Limited: revenues & profitability

Figure 174: China Grand Pharmaceutical and Healthcare Holdings Limited: assets & liabilities

    Pricing

Discounts available for multiple report purchases.

reportstore@marketline.com
+44 (0) 161 359 5817

Saved reports